Inhibition of pituitary hormones may occur with SIGNIFOR treatment. Monitoring of pituitary function should occur prior to initiation of therapy and periodically during treatment with SIGNIFOR.
A SHARED COMMITMENT TO ENHANCED PITUITARY CARE
Through PEAK, support is available to help eligible patients:
PEAK aims to make it easier for patients to find the support they need.
HOW TO CONTACT PEAK
By phone: 1-877-503-3377
Support for Patients includes:
You may be eligible for immediate co-pay savings on your next prescription:
To find out if you are eligible to save on your next prescription, call 1-877-577-7756.
Terms and Conditions
Valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Offer not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. This card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt, of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2017.
SIGNIFOR® (pasireotide) Injection, for subcutaneous use
SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The most common adverse reactions (frequency ≥20% in either group) occurring in patients receiving SIGNIFOR in clinical trials were:
Please see full Prescribing Information.